Zoetis Inc (ZTS) - Total Liabilities
Based on the latest financial reports, Zoetis Inc (ZTS) has total liabilities worth $9.76 Billion USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Zoetis Inc cash flow conversion to assess how effectively this company generates cash.
Zoetis Inc - Total Liabilities Trend (2010–2024)
This chart illustrates how Zoetis Inc's total liabilities have evolved over time, based on quarterly financial data. Check Zoetis Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Zoetis Inc Competitors by Total Liabilities
The table below lists competitors of Zoetis Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ASE Industrial Holding Co Ltd ADR
NYSE:ASX
|
USA | $515.97 Billion |
|
Bayerische Motoren Werke Aktiengesellschaft
XETRA:BMW
|
Germany | €166.41 Billion |
|
Discover Financial Services
NYSE:DFS
|
USA | $128.95 Billion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥8.30 Billion |
|
Danone SA
PA:BN
|
France | €27.84 Billion |
|
China Citic Bank Corp Ltd Class A
SHG:601998
|
China | CN¥9.03 Trillion |
|
Teradyne Inc
NASDAQ:TER
|
USA | $1.37 Billion |
Liability Composition Analysis (2010–2024)
This chart breaks down Zoetis Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Zoetis Inc (ZTS) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.64 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.81 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zoetis Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zoetis Inc (2010–2024)
The table below shows the annual total liabilities of Zoetis Inc from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $9.47 Billion | +1.85% |
| 2023-12-31 | $9.29 Billion | -11.66% |
| 2022-12-31 | $10.52 Billion | +12.46% |
| 2021-12-31 | $9.36 Billion | -4.88% |
| 2020-12-31 | $9.84 Billion | +11.30% |
| 2019-12-31 | $8.84 Billion | +2.85% |
| 2018-12-31 | $8.59 Billion | +26.35% |
| 2017-12-31 | $6.80 Billion | +10.57% |
| 2016-12-31 | $6.15 Billion | -9.85% |
| 2015-12-31 | $6.82 Billion | +29.92% |
| 2014-12-31 | $5.25 Billion | -6.17% |
| 2013-12-31 | $5.60 Billion | +151.96% |
| 2012-12-31 | $2.22 Billion | +12.46% |
| 2011-12-31 | $1.98 Billion | +1.80% |
| 2010-12-31 | $1.94 Billion | -- |
About Zoetis Inc
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and… Read more